MYDA Advisors’s Maravai LifeSciences MRVI Stock Holding History

MYDA Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$561K	–	317
2020 Q4	$561K	Buy	+20,000	New	+$557K	0.17%	114

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MYDA Advisors's MRVI Position: Q1 2021 in Review

MYDA Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2021, closing a stake of 20,000 shares — an estimated $561K sold.

MYDA Advisors first reported a position in MRVI in Q4 2020 and held it in 1 quarter. The position peaked at $561K in Q4 2020. 144 funds tracked by Wall St. Rank hold MRVI as of Q1 2021.

MYDA Advisors reported no remaining Maravai LifeSciences position as of Q1 2021 after selling out during the quarter.
MYDA Advisors sold 20,000 Maravai LifeSciences shares in Q1 2021, an estimated $561K.
MYDA Advisors first reported a position in Maravai LifeSciences in Q4 2020 and held it in 1 quarter.
MYDA Advisors's Maravai LifeSciences position peaked at $561K in Q4 2020.
144 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2021.

Based on MYDA Advisors's 13F filing for Q1 2021, filed 12 May 2021.